New Immunotherapy Combination Study for Nasopharyngeal Cancer Demonstrates Effectiveness of Lunit AI as Predictive Aid in Treatment Outcome–Published in Clinical Cancer Research

Recent clinical trial on combination immunotherapy for nasopharyngeal cancer provides evidence for Lunit SCOPE IO’s ability to predict patient response. Analysis indicates Immune-excluded Immune Phenotype acts as a resistance mechanism against combination immunotherapy, further supporting Lunit SCOPE IO’s ability to optimize cancer treatment selection.

SEOUL, South Korea, Aug. 1, 2022 /PRNewswire/ — A new phase II clinical trial validated the efficacy of Lunit’s AI biomarker, Lunit SCOPE IO, in predicting outcomes of immunotherapy in patients with nasopharyngeal carcinoma. The study has been published in Clinical Cancer Research.

Nasopharyngeal carcinoma (NPC) is a common type of cancer concentrated in Southeast Asia and Northern Africa. While platinum-based combination chemotherapy is the standard treatment for patients with recurrent or metastatic NPC, prognosis for patients for whom this therapy fails is poor, with limited treatment options remaining.

A study was conducted by researchers from eight South Korean institutions to evaluate the efficacy and safety of combined immunotherapy in recurrent or metastatic NPC patients for whom platinum-based chemotherapy had failed. Immunotherapy drug nivolumab and chemotherapy drug gemcitabine were administered in combination to these nasopharyngeal cancer patients, achieving an objective response rate (ORR) of 36.1% and 13.8 months of median progression-free survival (PFS).

In addition, researchers deployed Lunit SCOPE IO to analyze patients’ pathological samples in the process of identifying potential biomarkers.


Lunit SCOPE IO analyzes a patient’s cancer tissue slide image by observing the distribution of tumor-infiltrating lymphocytes (TIL), one of the primary immunocytes that fight cancer cells. Based on the spatial distribution pattern of TILs and cancer cells in the tumor microenvironment, Lunit SCOPE IO identifies the tissue sample as one of three immune phenotypes: inflamed, immune-excluded, or immune-desert.

The Inflamed Immune Phenotype, as identified by Lunit SCOPE IO, showed a high correlation with favorable immunotherapy outcomes, indicating potential as a practical biomarker. Furthermore, the Immune-excluded Phenotype was correlated with inferior ORR and PFS, indicating that the spatial distribution pattern of the Immune-excluded Phenotype acts as a resistance mechanism against combined nivolumab and gemcitabine treatment.

“This study shows that, by applying Lunit SCOPE IO to a clinical trial, it is possible to find a target group that responds better to treatment,” said Chan-Young Ock, Chief Medical Officer at Lunit. “This is an important case showing that Lunit SCOPE IO can be applied not only to single-drug immunotherapies, but also to combination immunotherapies.”

Clinical Cancer Research is a peer-reviewed medical journal on oncology published by the American Association for Cancer Research (AACR), with an impact factor of 13.8.

Lunit has continued to publish research results on the effectiveness of its AI biomarker in various peer-reviewed oncology journals. Following publications in the Journal of Clinical Oncology (JCO) and the European Journal of Cancer (EJC), this is the third study on Lunit SCOPE to be published in an international medical journal.